Pharmaceuticals
News Releases
2021
December
November
Nutraceuticals
Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctuations -
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Corporate
Otsuka Group Supports Recommendations of the Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
October
Pharmaceuticals
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
September
Pharmaceuticals
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuticals
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka announces that Novartis Pharma's ENTRESTO® received a new indication for treatment of hypertension in Japan
Corporate
100th Anniversary of Otsuka Group of Companies Looking Ahead to the Next 100 Years
August
Pharmaceuticals
Otsuka to Launch AJOVY® Subcutaneous Injection 225 mg Syringe in Japan
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
Pharmaceuticals
Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets
Pharmaceuticals
Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderline personality disorder
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Nutraceuticals
Production and Sales of Fibe-Mini Begin in Indonesia
July
Nutraceuticals
Reflecting Customer Concerns Introduction of ORONAMIN C DRINK in Label-free Bottles
Nutraceuticals
U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Uqora, a provider of women's urinary tract health products
Pharmaceuticals
Otsuka Files Application in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
June
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Otsuka Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
AJOVY® Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
Pharmaceuticals
Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Pharmaceuticals
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Corporate
Otsuka Group Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-
Pharmaceuticals
Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
April
Corporate
Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines
Corporate
Otsuka Pharmaceutical Receives First Certification as Tokyo Metropolitan Government Sports Promotion Model Company (Practical Division) Recognized for providing opportunities for exercise adapted for new lifestyles
Pharmaceuticals
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
March
Pharmaceuticals
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy
February
Nutraceuticals
Convenient Sizes of UL·OS Medicated Scalp Shampoo and Medicated Skin Wash Launched to Promote Trial Use
Corporate
Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan
Corporate
Office Divisions of Five Otsuka Group Companies to Switch to Green Power
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
Corporate